

Item 8.01. Other Events.

On April 20, 2017, we issued a press release to provide an update for our ongoing U.S. Phase 3 “LOCK-IT 100” clinical study of our lead product Neutrolin®.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)
Exhibits

Exhibit No.
Description

99.1
Press release dated April 20, 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: April 20, 2017 By: /s/ Robert W. Cook
Robert W. Cook
Chief Financial Officer